Protagonist Therapeutics Inc (PTGX)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 99.61% | 99.21% | 98.94% | 98.95% | 94.48% | — | — | -224.10% | 89.52% | 90.49% | 94.51% | 96.48% | 97.01% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -19.67% |
| Operating profit margin | 58.20% | 46.05% | 47.71% | 47.21% | -156.09% | — | — | -17,029.45% | -494.24% | -374.66% | -293.50% | -262.18% | -460.01% | -441.41% | -299.45% | -220.85% | -225.36% | -245.11% | -432.79% | -3,691.54% |
| Pretax margin | 64.32% | 53.45% | 54.09% | 52.53% | -131.59% | — | — | -16,319.91% | -479.26% | -369.64% | -291.70% | -261.21% | -458.94% | -440.88% | -299.39% | -221.17% | -226.51% | -243.62% | -426.64% | -3,617.90% |
| Net profit margin | 63.34% | 52.76% | 53.26% | 51.47% | -127.76% | — | — | -15,542.03% | -462.08% | -364.93% | -290.41% | -260.83% | -458.94% | -440.88% | -299.39% | -224.79% | -231.07% | -252.03% | -438.96% | -3,587.75% |
Protagonist Therapeutics Inc's profitability ratios have shown significant fluctuations over the past few years. The gross profit margin, which reflects the percentage of revenue retained after accounting for the cost of goods sold, has varied, starting from a negative figure in March 2020, reaching 100% in mid-2020, and then declining to around 90% by the end of 2022 before recovering slightly in 2024.
The operating profit margin, indicating the company's operating efficiency and profitability before interest and taxes, also experienced volatility. Protagonist Therapeutics Inc reported negative operating profit margins throughout 2020 and most of 2021, reflecting operational challenges. From 2023 onwards, there was a significant improvement, with margins turning positive by March 2024, reaching around 58% in December 2024.
Similarly, the pretax margin, which measures the company's profitability relative to its total revenue, followed a similar trend. After recording negative margins in the earlier years, there was a notable recovery in profitability from 2023 onwards, with margins turning positive and increasing steadily through 2024.
Lastly, the net profit margin, which indicates the company's bottom-line profitability after accounting for all expenses and taxes, showed a pattern of improvement from 2023 onwards. Starting from substantial negative margins, Protagonist Therapeutics Inc managed to achieve positive net profit margins by March 2024, reaching around 63% by December 2024.
Overall, Protagonist Therapeutics Inc's profitability ratios reflect a challenging period of losses initially, followed by a recovery and improvement in profitability indicators towards the end of the period analyzed.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 33.95% | 24.69% | 24.77% | 23.63% | -26.16% | -46.43% | -45.93% | -60.99% | -52.99% | -46.73% | -42.99% | -35.30% | -36.19% | -28.85% | -20.16% | -23.10% | -19.88% | -28.98% | -32.17% | -63.43% |
| Return on assets (ROA) | 36.95% | 28.29% | 27.65% | 25.76% | -21.42% | -40.99% | -40.98% | -55.66% | -49.54% | -45.52% | -42.54% | -35.11% | -36.11% | -28.81% | -20.16% | -23.51% | -20.39% | -29.80% | -32.63% | -61.65% |
| Return on total capital | 37.31% | 27.87% | 27.81% | 26.23% | -28.31% | — | -49.54% | — | — | -54.22% | -49.89% | -40.94% | — | -32.77% | -22.98% | -26.78% | — | -37.16% | -42.94% | -135.88% |
| Return on equity (ROE) | 40.75% | 32.12% | 31.40% | 28.93% | -22.77% | — | -44.66% | — | — | -52.73% | -49.29% | -40.53% | — | -32.62% | -22.80% | -27.02% | — | -38.19% | -43.83% | -132.71% |
Protagonist Therapeutics Inc's profitability ratios exhibit a fluctuating trend over the quarters analyzed.
- Operating return on assets (Operating ROA) was negative throughout the period, reaching its lowest point at -60.99% in March 2023. However, there was a significant improvement in profitability in the subsequent quarters, with the ratio turning positive in March 2024 at 23.63% and continuing to increase to 33.95% by December 2024. This indicates the company's effectiveness in generating operating profit from its assets in the latter part of the period.
- Return on assets (ROA) followed a similar pattern, with negative values from March 2020 to December 2023. The ratio turned positive in March 2024 at 25.76% and continued to rise, reaching 36.95% by December 2024. This improvement suggests a positive trend in the company's ability to generate profit from its assets.
- Return on total capital was negative for most quarters analyzed. Notably, there were gaps in data for December 2020 and subsequent periods. The ratio improved towards the end of the period, with positive values starting from March 2024 at 26.23% and increasing to 37.31% by December 2024. This indicates that the company's profitability in relation to its total capital improved significantly in the later quarters.
- Return on equity (ROE) also exhibited a similar trend, remaining negative for the majority of the period. However, there was a notable improvement in profitability in the later quarters, with the ratio turning positive in March 2024 at 28.93% and continuing to increase to 40.75% by December 2024. This suggests that the company's profitability from shareholders' equity improved significantly towards the end of the period.
Overall, Protagonist Therapeutics Inc showed a trend of increasing profitability ratios in the latter part of the period analyzed, indicating an improvement in its ability to generate profits from its assets, capital, and equity. This positive trend in profitability metrics is a promising sign for the company's financial performance and future prospects.